Serebellum ve Beyin Sapının Heredodejeneratif Hastalıkları
Özet
Serebellum ve beyin sapını etkileyen heredodejeneratif hastalıklar; kalıtım şekillerine, klinik bulgulara ve eşlik eden nörolojik belirtilere göre sınıflandırılan karmaşık bir gruptur. Herediter ataksiler, Friedreich ataksisi gibi daha sık görülen tiplerin yanı sıra metabolik ve mitokondriyal kökenli nadir tabloları da kapsar. Herediter spastik paraparazi, kortikospinal traktus dejenerasyonuyla karakterize olup spastisite ve güçsüzlükle seyrederken, serebellar hipoplazi ve pontoserebellar hipoplaziler ise serebellar volüm kaybı ve çeşitli gelişimsel anomalilerle kendini gösterir. Bu hastalıkların tanısında genetik testler ve kraniyal görüntülemeler önemli rol oynarken, tedavide temel amaç semptomların yönetimi ve rehabilitasyon sürecinin desteklenmesidir.
Heredodegenerative diseases affecting the cerebellum and brainstem constitute a complex group classified by inheritance patterns, clinical findings, and associated neurological symptoms. Hereditary ataxias include common conditions like Friedreich's ataxia as well as rare metabolic and mitochondrial disorders. Hereditary spastic paraplegia is characterized by the progressive degeneration of the corticospinal tract, presenting with spasticity and weakness, whereas cerebellar hypoplasia and pontocerebellar hypoplasias manifest through cerebellar volume loss and various developmental anomalies. While genetic testing and neuroimaging play critical roles in diagnosis, management primarily focuses on symptom control and supportive rehabilitation.
Referanslar
Brusse E, Maat-Kievit JA, van Swieten JC. Diagnosis and management of early- and late-onset cerebellar ataxia. Clin Genet. 2007; 71:12.
Jayadev, S., Bird, T. Hereditary ataxias: overview. Genet Med. 2013;15, 673–683.
Dürr A, Cossee M, Agid Y, et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996; 335:1169.
Epplen C, Epplen JT, Frank G, et al. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet. 1997; 99:834.
Cossée M, Schmitt M, Campuzano V, et al. Evolution of the Friedreich's ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A. 1997; 94:7452.
Filla A, De Michele G, Cavalcanti F, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996; 59:554.
Harding AE. Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981; 104: 589.
Koeppen AH. Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J Neurol Sci. 2011; 303:1.
Schulz JB, Dehmer T, Schöls L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000; 55:1719.
Sherer T, Greenamyre JT. A therapeutic target and biomarker in Friedreich's ataxia. Neurology 2000; 55:1600.
Campuzano V, Montermini L, Lutz Y, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet. 1997; 6:1771.
Priller J, Scherzer CR, Faber PW, et al. Frataxin gene of Friedreich's ataxia is targeted to mitochondria. Ann Neurol. 1997; 42:265.
Babcock M, de Silva D, Oaks R, et al. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997; 276:1709.
Tan G, Chen LS, Lonnerdal B, et al. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum Mol Genet. 2001; 10:2099.
Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58:495.
Delatycki MB, Corben LA. Clinical features of Friedreich ataxia. J Child Neurol 2012; 27:1133.
Collins A. Clinical neurogenetics: friedreich ataxia. Neurol Clin. 2013; 31:1095.
Ribaï P, Pousset F, Tanguy ML, et al. Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol. 2007; 64:558.
Delatycki MB, Paris DB, Gardner RJ, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999; 87:168.
Wüllner U, Klockgether T, Petersen D, et al. Magnetic resonance imaging in hereditary and idiopathic ataxia. Neurology. 1993; 43:318.
Schulz JB, Boesch S, Bürk K, et al. Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol. 2009; 5:222.
Child JS, Perloff JK, Bach PM, et al. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J Am Coll Cardiol. 1986; 7:1370.
Payne RM, Wagner GR. Cardiomyopathy in Friedreich ataxia: clinical findings and research. J Child Neurol. 2012; 27:1179.
Mejia E, Lynch A, Hearle P, et al. Ectopic Burden via Holter Monitors in Friedreich Ataxia. Pediatr Neurol. 2021; 117:29.
Lodi R, Hart PE, Rajagopalan B, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann Neurol. 2001; 49:590.
Hart PE, Lodi R, Rajagopalan B, et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol. 2005; 62:621.
Pandolfo M, Arpa J, Delatycki MB, et al. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann Neurol. 2014; 76:509.
Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol. 2007; 6:245.
Lutz R, Bodensteiner J, Schaefer B, Gay C. X-linked olivopontocerebellar atrophy. Clin Genet. 1989; 35:417.
Spira PJ, McLeod JG, Evans WA. A spinocerebellar degeneration with X-linked inheritance. Brain. 1979; 102:27.
Kremer H, Hamel BC, van den Helm B, et al. Localization of the gene (or genes) for a syndrome with X-linked mental retardation, ataxia, weakness, hearing impairment, loss of vision and a fatal course in early childhood. Hum Genet. 1996; 98:513.
Synofzik M, Puccio H, Mochel F, Schöls L. Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies. Neuron. 2019; 101:560.
Batshaw ML, Msall M, Beaudet AL, Trojak J. Risk of serious illness in heterozygotes for ornithine transcarbamylase deficiency. J Pediatr. 1986; 108:236.
Yudkoff M, Daikhin Y, Nissim I, et al. In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. J Clin Invest. 1996; 98:2167.
Gaspari R, Arcangeli A, Mensi S, et al. Late-onset presentation of ornithine transcarbamylase deficiency in a young woman with hyperammonemic coma. Ann Emerg Med. 2003; 41:104.
Seow HF, Bröer S, Bröer A, et al. Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet. 2004; 36:1003.
Hasan SM, D'Adamo MC. GeneReviews®, Adam MP, Ardinger HH, Pagon RA, et al. (Eds), University of Washington, Seattle, Seattle (WA) 1993. www.ncbi.nlm.nih.gov/books/NBK25442/ (December 11, 2018).
Steckley JL, Ebers GC, Cader MZ, McLachlan RS. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology. 2001; 57:1499.
Tomlinson SE, Rajakulendran S, Tan SV, et al. Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1. J Neurol Neurosurg Psychiatry. 2013; 84:1107.
Graves TD, Cha YH, Hahn AF, et al. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain. 2014; 137:1009.
Scheffer H, Brunt ER, Mol GJ, et al. Three novel KCNA1 mutations in episodic ataxia type I families. Hum Genet. 1998; 102:464.
Tacik P, Guthrie KJ, Strongosky AJ, et al. Whole-exome sequencing as a diagnostic tool in a family with episodic ataxia type 1. Mayo Clin Proc. 2015; 90:366.
Zasorin NL, Baloh RW, Myers LB. Acetazolamide-responsive episodic ataxia syndrome. Neurology. 1983; 33:1212.
Spacey S. Episodic ataxia type 2. In: GeneReviews 2011.
Yue Q, Jen JC, Thwe MM, et al. De novo mutation in CACNA1A caused acetazolamide-responsive episodic ataxia. Am J Med Genet. 1998; 77:298.
Cader MZ, Steckley JL, Dyment DA, et al. A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia. Neurology. 2005; 65:156.
Herrmann A, Braathen GJ, Russell MB. [Episodic ataxias]. Tidsskr Nor Laegeforen. 2005; 125:2005.
Kono N, Ohto U, Hiramatsu T, et al. Impaired α-TTP-PIPs interaction underlies familial vitamin E deficiency. Science. 2013; 340:1106.
Yokota T, Shiojiri T, Gotoda T, et al. Friedreich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein gene. Ann Neurol 1997; 41:826.
https://www.uptodate.com/contents/overview-of-the-hereditary-ataxias.
